Publications

Covington TR, Gentry PR, Van Landingham CB, Andersen ME, Kester JE, Clewell HJ. 2007. The use of Markov chain MonteCarlo uncertainty analysis to support a Public Health Goal for perchloroethylene. Regul Toxicol Pharmacol 47(1):1–18; doi: 10.1080/20024091064264. PMID: 16901594.

Woods CG, Burns AM, Maki A, Bradford BU, Cunningham ML, Connor HD, Kadiiska MB, Mason RP, et al. 2007. Sustained formation of alpha-(4-pyridyl-1-oxide)-N-tert-butylnitrone radical adducts in mouse liver by peroxisome proliferators is dependent upon peroxisome proliferator-activated receptor-alpha, but not NADPH oxidase. Free Radic Biol Med 42(3):335-342; doi: 10.1016/j.freeradbiomed.2006.10.053. PMID: 17210446.

Paustenbach DJ, Panko JM, Scott PK, Unice KM. 2007. A methodology for estimating human exposure to perfluorooctanoic acid (PFOA): A retrospective exposure assessment of a community (1951-2003). J Toxicol Environ Health A 70(1):28–57; doi: 10.1080/15287390600748815. PMID: 17162497.

Urban JD, Vargas G, von Zastrow M, Mailman RB. 2007. Aripiprazole has functionally selective actions at D2 receptor-mediated signaling pathways. Neuropsychopharmacol 32(1):67-77; doi: 10.1038/sj.npp.1301071. PMID: 16554739.

Rogers JM. 2006. Casting a broad network: Fishing for mechanisms of retinoid teratogenicity. Toxicological highlight. Toxicol Sci 94(1):1–2; doi: 10.1093/toxsci/kfl104. PMID: 17167877.

Staskal DF, Hakk H, Bauer D, Diliberto JJ, Birnbam LS. 2006. Toxicokinetics of polybrominated diphenyl ether congeners 47, 99, 100, and 153 in mice. Toxicol Sci 94(1):28-37; doi: 10.1093/toxsci/kfl091. PMID: 16936226.

Cher DJ, Deubner DC, Kelsh MA, Chapman PS, Ray RM. 2006. Assessment of the beryllium lymphocyte proliferation test using statistical process control. Inhal Toxicol 18(11):901–910; doi: 10.1080/08958370600822631. PMID: 16864408.

Alexander DD, Mink PJ, Mandel JH, Kelsh MA. 2006. A meta-analysis of occupational trichloroethylene exposure and multiple myeloma or leukemia. Occup Med 56(7):485–493; doi: 10.1093/occmed/kql083. PMID: 16905622.

Becker DS, Long ER, Proctor DM, Ginn TC. 2006. Toxicity and bioavailability of chromium in sediments associated with chromite ore processing residue. Environ Toxicol Chem 25(10):2576–2583; doi: 10.1897/05-494R.1. PMID: 17022396.

Van den Berg M, Birnbaum L, Denison M, De Vito M, Farland W, Feeley M, Fiedler H,…, Haws LC, et al. 2006. The 2005 World Health Organization reevaluation of human and mammalian toxic equivalency factors for dioxins and dioxin-like compounds. Toxicol Sci 93(2):223-241; doi: 10.1093/toxsci/kfl055. PMID: 16829543.

Mandel JH, Kelsh MA, Mink PJ, Alexander D, Kalmes RM, Weingart M, et al. 2006. Occupational trichloroethylene exposure and non-Hodgkins lymphoma: A meta-analysis and review. Occup Environ Med 63(9):597–607; doi: 10.1136/oem.2005.022418. PMID: 16644896.

Barone S Jr., Brown RC, Euling S, Cohen Hubal E, Kimmel CA, Makris S, Moya J,…,  Thompson CM. 2006. Visión general de la evaluación del rieso en salud infantil empleando un enfoque por etapas de desarrollo. Acta Toxicol Argent 14(Suppl):7–10.

Rose WC, Marathe PH, Jang G, Monticello TM, Balasubramanian BN, Long B, Fairchild C, Wall ME, Wani MC. 2006. Novel fluoro-substituted campthothecins: In vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization. Cancer Chemother Pharmacol 58(1):73-85; doi: 10.1007/s00280-005-0128-y. PMID: 16228206.

David RM, Clewell HJ, Gentry PR, Covington TR, Morgott DA, Marino DJ. 2006. Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations. Regul Toxicol Pharmacol 45(1):55–65; doi: 10.1016/j.yrtph.2005.12.003. PMID: 16439044.

Marino DJ, Clewell HJ, Gentry PR, Covington TR, Hack CE, David RM, Morgott DA. 2006. Revised assessment of cancer risk to dichloromethane: Part I Bayesian PBPK and dose-response modeling in mice. Regul Toxicol Pharmacol 45(1):44–54; doi: 10.1016/j.yrtph.2005.12.007. PMID: 16442684.

Degregorio MW, Dingley KH, Wurz GT, Ubick E, Turteltaub KW. 2006. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations. Cancer Chemother Pharmacol 57(3):335-342; doi: 10.1007/s00280-005-0060-1. PMID: 16047147.

Tompkins EM, Farmer PB, Lamb JH, Jukes R, Dingley K, Ubick E, et al. 2006. A novel 14C-postlabeling assay using accelerator mass spectrometry for the detection of O6-methyldeoxy-guanosine adducts. Rapid Commun Mass Spectrom 20(5):883–891; doi: 10.1002/rcm.2370. PMID: 16470516.

Borowsky AD, Dingley KH, Ubick E, Turteltaub KW, Cardiff RD, Devere-White R. 2006. Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model. Neoplasia 8(9):708–715; doi: 10.1593/neo.06373. PMID: 16984728.

Malfatti MA, Dingley KH, Nowell-Kadlubar S, Ubick EA, Mulakken N, Nelson D, Lang NP, et al. 2006. The urinary metabolite profile of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is predictive of colon DNA adducts after a low-dose exposure in humans. Cancer Res 66(21):10541–10547; doi: 10.1158/0008-5472.CAN-06-1573. PMID: 17079477.

Wheeler MW, Park RM, Bailer AJ. 2006. Comparing median lethal concentration values using confidence interval overlap or ratio tests. Environ Toxicol Chem 25(5):1441-4; doi: 10.1897/05-320r.1. PMID: 16704080.